As a sole generic, they'll price at a 15-20% discount, tops. IMO. Sanofi will also be incentivized to raise their branded pricing if they can get away with it which would creep generic pricing higher.
My recent post and the earlier one are based on the same concept, maximizing profits when introducing a generic. I think both posts are consistent and I stand by them. The recent post reflects the greater understanding of how MNTA and NVS will share the revenue stream.
You are right that I should have described the generic from SNY as an authorized-generic.
Market Data 
Markets 
AI
